Inozyme Pharma, Inc.
INZYDelisted Jul 1, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001693011
Inozyme Pharma, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 3, 2025; 87 institutions reported holding it in 13F filings for Q2 2025, worth $202.3M in total; no superinvestor held it.
Q3 2021 vs. Q2 2021
How the institutions holding Inozyme Pharma, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 50 | 52 | +2 |
| Shares | 19.8M | 17.5M | −2.30M (−11.6%) |
| Value | $337.1M | $202.7M | −$134.4M (−39.9%) |
New holders (6)
Institutions that held Inozyme Pharma, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| MPM Oncology Impact Management LP | 320,724 | $3.72M | 0.58% |
| Caas Capital Management LP | 135,398 | $1.57M | 0.12% |
| Laurion Capital Management LP | 70,700 | $819.0K | 0.01% |
| Jacobs Levy Equity Management, Inc | 21,037 | $244.0K | 0.00% |
| SG Americas Securities, LLC | 11,611 | $135.0K | 0.00% |
| Acadian Asset Management LLC | 3,676 | $42.0K | 0.00% |
Sold out (4)
Institutions that held Inozyme Pharma, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Ra Capital Management, L.P. | 2,003,653 | $34.1M |
| Novo Holdings A/S | 1,867,706 | $31.8M |
| Burrage Capital Management LLC | 242,517 | $4.13M |
| UBS Group AG | 48 | $1.00K |